Bone health evaluation one year after aromatase inhibitors completion

Breast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. However, there is little information about bone mineral density (BMD) after completing AI-treatment. The present study aimed to assess BMD changes one year after AI-therapy completion.

Source: Bone - September 14, 2018 Category: Orthopaedics Authors: Marta Pineda-Moncus í, Sonia Servitja, Guillem Casamayor, Maria Lourdes Cos, Abora Rial, Jaime Rodriguez-Morera, Ignasi Tusquets, Adolfo Diez-Perez, Natalia Garcia-Giralt, Xavier Nogués Tags: Full Length Article Source Type: research